z-logo
Premium
Exploring effects of a natural combination medicine on exercise‐induced inflammatory immune response: A double‐blind RCT
Author(s) -
Pilat C.,
Frech T.,
Wagner A.,
Krüger K.,
Hillebrecht A.,
PonsKühnemann J.,
Scheibelhut C.,
Bödeker R.H.,
Mooren F.C.
Publication year - 2015
Publication title -
scandinavian journal of medicine and science in sports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.575
H-Index - 115
eISSN - 1600-0838
pISSN - 0905-7188
DOI - 10.1111/sms.12265
Subject(s) - randomized controlled trial , immune system , medicine , double blind , physical therapy , immunology , alternative medicine , placebo , pathology
Traumeel ( T r14) is a natural, combination drug, which has been shown to modulate inflammation at the cytokine level. This study aimed to investigate potential effects of T r14 on the exercise‐induced immune response. In a double‐blind, randomized, controlled trial, healthy, untrained male subjects received either T r14 ( n =  40) or placebo ( n =  40) for 24 h after a strenuous experimental exercise trial on a bicycle (60 min at 80% VO 2 max ). A range of antigen‐stimulated cytokines ( in vitro ), white blood cell count, lymphocyte activation and apoptosis markers, and indicators of muscle damage were assessed up to 24 h following exercise. The area under the curve with respect to the increase ( AUC I ) was compared between both groups. The T r14 group showed a reduced exercise‐induced leukocytosis and neutrocytosis ( P  < 0.01 for both), a higher AUC I score of antigen‐stimulated IL ‐1β and IL ‐1α (absolute and per monocyte, all P  < 0.05), a lower AUC I score of antigen‐stimulated GM ‐ CSF ( P  < 0.05) and by trend a lower AUC I score of antigen‐stimulated IL ‐2 and IL ‐4 as well as a higher AUC I score of antigen‐stimulated IL ‐6 (all P  < 0.1). T r14 might promote differentiated effects on the exercise‐induced immune response by (a) decreasing the inflammatory response of the innate immune system; and (b) augmenting the pro‐inflammatory cytokine response.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here